From SEC filing today - IncellDx has submitted
Post# of 148168
Quote:
IncellDx has submitted patent applications in connection with certain uses of CCR5 antagonists in COVID-19. The Participants understand that those patent applications before the USPTO are currently pending (contrary to the assertions of the Company in the Federal Lawsuit) and have been advised by IncellDx that they do not directly conflict with patents held solely by the Company.
A complete lie.